Bausch Health Q2 2022 Earnings Report
Key Takeaways
Bausch Health reported revenues of $1.967 billion for Q2 2022, a 6% decrease compared to Q2 2021. The company intensified its focus on the Bausch Pharma and Solta businesses, advanced debt paydown through open market repurchases, and is committed to strategic alternatives.
Revenues reached $1.967 billion.
The company plans to appeal the anticipated court decision and defend XIFAXAN intellectual property.
The balance sheet improved through the early retirement of $481 million of long-term debt.
The company is committed to strategic alternatives and evaluates the distribution of Bausch + Lomb shares amid patent litigation.
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Forward Guidance
Bausch Health updated its consolidated guidance for the full year 2022 as follows: • Full year revenue range of $8.05 - $8.22 billion compared to prior guidance of $8.25 - $8.40 billion • Full year Adjusted EBITDA (non-GAAP)1 range of $3.02 - $3.12 billion compared to prior guidance of $3.225 - $3.375 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income